Combination chemotherapy for head and neck cancer: The addition of Bcl-2 inhibitors

Current Opinion in Investigational Drugs

Volumn 10, Issue 12, 2009, Pages 1325-1333

  Lo Russo, Lucio ^a   Lo Muzio, Lorenzo ^a,b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

Apoptosis; Bcl 2 inhibitor; BH3 mimetic; Combination chemotherapy; Head and neck cancer; Head and neck squamous cell carcinoma; HNSCC; Targeted therapy

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; APOGOSSYPOL; BCL 2 INHIBITOR; CHELERYTHRINE; CISPLATIN; EPIGALLOCATECHIN GALLATE; ERLOTINIB; GOSSYPOL; ISOSORBIDE; OBATOCLAX; OBLIMERSEN; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; SURVIVIN; TETROCARCIN A; TW 37; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MULTIPLE MYELOMA; MYELOMA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHARMACOGENOMICS; PROTEOMICS; RECURRENT CANCER; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DRUG DELIVERY SYSTEMS; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL;

EID: 71249162038     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Petersen P: The World Oral Health Report 2003: Continuous improvement of oral health in the 21st century - the approach of the WHO Global Oral Health Programme. Community Dent Oral Epidemiol (2003) 31(Suppl 1):3-23.
2. Hunter KD, Parkinson EK, Harrison PR: Profiling early head and neck cancer. Nat Rev Cancer (2005) 5(2):127-135.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin (2007) 57(1):43-66.
4. McGurk M, Chan C, Jones J, O'Regan E, Sherriff M: Delay in diagnosis and its effect on outcome in head and neck cancer. Br J Oral Maxillofac Surg (2005) 43(4):281-284.
5. Vikram B, Strong EW, Shah JP, Spiro R: Failure at the primary site following multimodality treatment in advanced head and neck cancer. Head Neck Surg (1984) 6(3):720-723. (Pubitemid 14185488)
6. Warnakulasuriya KA, Robinson D, Evans H: Multiple primary tumours following head and neck cancer in southern England during 1961-1998. J Oral Pathol Med (2003) 32(8): 443-449.
7. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH: A genetic explanation of Slaughter's concept of field cancerization: Evidence and clinical implications. Cancer Res (2003) 63(8):1727-1730.
8. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z: Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA (2000) 97(13):7124-7129.
9. Choong N, Vokes E: Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin (2008) 58(1):32-53.
10. Specenier PM, Vermorken JB: Current concepts for the management of head and neck cancer: Chemotherapy. Oral Oncol (2009) 45(4-5):409-415.
11. Specenier PM, Vermorken JB: Recurrent head and neck cancer: Current treatment and future prospects. Expert Rev Anticancer Ther (2008) 8(3):375-391.
12. Rapidis AD, Vermorken JB, Bourhis J: Targeted therapies in head and neck cancer: Past, present and future. Rev Recent Clin Trials (2008) 3(3):156-166.
13. Kang MH, Reynolds CP: Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res (2009) 15(4):1126-1132.
14. Tsujimoto Y, Cossman J, Jaffe E, Croce CM: Involvement of the Bcl-2 gene in human follicular lymphoma. Science (1985) 228(4706):1440-1443.
15. Gastman BR: Apoptosis and its clinical impact. Head Neck (2001) 23(5):409-425.
16. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC: Investigation of the subcellular distribution of the Bcl-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res (1993) 53(19):4701-4714.
17. Reed JC: Promise and problems of Bcl-2 antisense therapy. J Natl Cancer Inst (1997) 89(14):988-990.
18. Reed JC: Bcl-2 family proteins. Oncogene (1998) 17(25): 3225-3236.
19. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB et al: Structure of Bcl-XL-Bak peptide complex: Recognition between regulators of apoptosis. Science (1997) 275(5302): 983-986.
20. Opferman JT, Korsmeyer SJ: Apoptosis in the development and maintenance of the immune system. Nat Immunol (2003) 4(5):410-415.
21. Baell JB, Huang DC: Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem Pharmacol (2002) 64(5-6):851-863.
22. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB: BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev (2001) 15(12):1481-1486.
23. Willis SN, Adams JM: Life in the balance: How BH3-only proteins induce apoptosis. Curr Opin Cell Biol (2005) 17(6): 617-625.
24. Skommer J, Wlodkowic D, Deptala A: Larger than life: Mitochondria and the Bcl-2 family. Leuk Res (2007) 31(3): 277-286.
25. Zeitlin BD, Joo E, Dong Z, Warner K, Wang G, Nikolovska-Coleska Z, Wang S, Nor JE: Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res (2006) 66(17):8698-8706.
26. Karl E, Warner K, Zeitlin B, Kaneko T, Wurtzel L, Jin T, Chang J, Wang S, Wang CY, Strieter RM, Nunez G et al: Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-?B and CXC chemokines. Cancer Res (2005) 65(12): 5063-5069.
27. Kaneko T, Zhang Z, Mantellini MG, Karl E, Zeitlin B, Verhaegen M, Soengas MS, Lingen M, Strieter RM, Nunez G, Nor JE: Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res (2007) 67(20): 9685-9693.
28. Krajewski S, Chatten J, Hanada M, Reed JC: Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastomas. Comparisons with tumor cell differentiation and N-Myc protein. Lab Invest (1995) 72(1):42-54.
29. Krajewski S, Bodrug S, Gascoyne R, Berean K, Krajewska M, Reed JC: Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol (1994) 145(3):515-525.
30. Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen K: Apoptosis suppressing protein Bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol (1995) 177(1):49-55.
31. Chan WK, Mole MM, Levison DA, Ball RY, Lu QL, Patel K, Hanby AM: Nuclear and cytoplasmic Bcl-2 expression in endometrial hyperplasia and adenocarcinoma. J Pathol (1995) 177(3): 241-246.
32. Bronner MP, Culin C, Reed JC, Furth EE: The Bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol (1995) 146(1):20-26.
33. Tron VA, Krajewski S, Klein-Parker H, Li G, Ho VC, Reed JC: Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am J Pathol (1995) 146(3):643-650.
34. Mosnier JF, Perret AG, Brunon J, Boucheron S: Expression of the Bcl-2 oncoprotein in meningiomas. Am J Clin Pathol (1996) 106(5):652-659.
35. Sharma H, Sen S, Mathur M, Bahadur S, Singh N: Combined evaluation of expression of telomerase, survivin, and anti-apoptotic Bcl-2 family members in relation to loss of differentiation and apoptosis in human head and neck cancers. Head Neck (2004) 26(8):733-740.
36. Sharma H, Sen S, Lo Muzio L, Mariggio A, Singh N: Antisensemediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther (2005) 4(7):720-727.
37. Popovic B, Jekic B, Novakovic I, Lukovic LJ, Tepavcevic Z, Jurisic V, Vukadinovic M, Milasin J: Bcl-2 expression in oral squamous cell carcinoma. Ann NY Acad Sci (2007) 1095:19-25.
38. Lo Muzio L, Mignogna MD, Pannone G, Rubini C, Grassi R, Nocini PF, Ferrari F, Serpico R, Favia G, De Rosa G, Maiorano E: Expression of bcl-2 in oral squamous cell carcinoma: An immunohistochemical study of 90 cases with clinicopathological correlations. Oncol Rep (2003) 10(2):285-291.
39. Teni T, Pawar S, Sanghvi V, Saranath D: Expression of Bcl-2 and Bax in chewing tobacco-induced oral cancers and oral lesions from India. Pathol Oncol Res (2002) 8(2):109-114.
40. Trask DK, Wolf GT, Bradford CR, Fisher SG, Devaney K, Johnson M, Singleton T, Wicha M: Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope (2002) 112(4):638-644.
41. Stein CA, Benimetskaya L, Mani S: Antisense strategies for oncogene inactivation. Semin Oncol (2005) 32(6):563-572.
42. Oblimersen: Augmerosen, Bcl-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium. Drugs R D (2007) 8(5):321-334.
43. Piche A, Grim J, Rancourt C, Gomez-Navarro J, Reed JC, Curiel DT: Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res (1998) 58(10):2134-2140.
44. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, Wagner G, Verdine GL, Korsmeyer SJ: Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science (2004) 305(5689):1466-1470.
45. Oh KJ, Barbuto S, Pitter K, Morash J, Walensky LD, Korsmeyer SJ: A membrane-targeted BID Bcl-2 homology 3 peptide is sufficient for high potency activation of Bax in vitro. J Biol Chem (2006) 281(48):36999-37008.
46. Azmi AS, Mohammad RM: Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol (2009) 218(1):13-21.
47. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell (2000) 100(1):57-70.
48. Zeitlin BD, Zeitlin IJ, Nor JE: Expanding circle of inhibition: Small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol (2008) 26(25):4180-4188.
49. Zhang L, Ming L, Yu J: BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat (2007) 10(6):207-217.
50. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC: Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell (2005) 17(3):393-403.
51. Denicourt C, Dowdy SF: Medicine. Targeting apoptotic pathways in cancer cells. Science (2004) 305(5689):1411-1413.
52. Shangary S, Johnson DE: Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia (2003) 17(8):1470-1481.
53. Wang JL, Zhang ZJ, Choksi S, Shan S, Lu Z, Croce CM, Alnemri ES, Korngold R, Huang Z: Cell permeable Bcl-2 binding peptides: A chemical approach to apoptosis induction in tumor cells. Cancer Res (2000) 60(6):1498-1502.
54. Li R, Boehm AL, Miranda MB, Shangary S, Grandis JR, Johnson DE: Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells. Neoplasia (2007) 9(10):801-811.
55. Walensky LD, Pitter K, Morash J, Oh KJ, Barbuto S, Fisher J, Smith E, Verdine GL, Korsmeyer SJ: A stapled BID BH3 helix directly binds and activates Bax. Mol Cell (2006) 24(2):199-210.
56. Sadowsky JD, Fairlie WD, Hadley EB, Lee HS, Umezawa N, Nikolovska-Coleska Z, Wang S, Huang DC, Tomita Y, Gellman SH: (?/?+?)-peptide antagonists of BH3 domain/Bcl-XL recognition: Toward general strategies for foldamer-based inhibition of protein-protein interactions. J Am Chem Soc (2007) 129(1):139-154.
57. Petros AM, Nettesheim DG, Wang Y, Olejniczak ET, Meadows RP, Mack J, Swift K, Matayoshi ED, Zhang H, Thompson CB, Fesik SW: Rationale for Bcl-XL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci (2000) 9(12):2528-2534.
58. Ashimori N, Zeitlin BD, Zhang Z, Warner K, Turkienicz IM, Spalding AC, Teknos TN, Wang S, Nor JE: TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol Cancer Ther (2009) 8(4):893-903.
59. Labi V, Grespi F, Baumgartner F, Villunger A: Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: A breakthrough in anticancer therapy? Cell Death Differ (2008) 15(6):977-987.
60. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS: Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol (2009) 45(4-5):324-334.
61. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS et al: Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 10(1):105-115.
62. Chen C, Edelstein LC, Gelinas C: The Rel/NF-?B family directly activates expression of the apoptosis inhibitor Bcl-XL. Mol Cell Biol (2000) 20(8):2687-2695.
63. Deverman BE, Cook BL, Manson SR, Niederhoff RA, Langer EM, Rosova I, Kulans LA, Fu X, Weinberg JS, Heinecke JW, Roth KA et al: Bcl-XL deamidation is a critical switch in the regulation of the response to DNA damage. Cell (2002) 111(1):51-62.
64. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A: BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell (2007) 12(2):171-185.
65. An J, Chervin AS, Nie A, Ducoff HS, Huang Z: Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene (2007) 26(5):652-661.
66. Skommer J, Wlodkowic D, Matto M, Eray M, Pelkonen J: HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leuk Res (2006) 30(3):322-331.
67. Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Bruncko M, Deckwirth T, Frost DJ, Jarvis K, Joseph MK, Marsh K et al: A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res (2006) 66(17):8731-8739.
68. Oliver CL, Bauer JA, Wolter KG, Ubell ML, Narayan A, O'Connell KM, Fisher SG, Wang S, Wu X, Ji M, Carey TE et al: In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res (2004) 10(22):7757-7763.
69. Bauer JA, Trask DK, Kumar B, Los G, Castro J, Lee JS, Chen J, Wang S, Bradford CR, Carey TE: Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: Role of wild-type p53 and Bcl-XL. Mol Cancer Ther (2005) 4(7):1096-1104.
70. Cory S, Vaux DL, Strasser A, Harris AW, Adams JM: Insights from Bcl-2 and Myc: Malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res (1999) 59(7 Suppl):1685s-1692s.
71. Wolter KG, Wang SJ, Henson BS, Wang S, Griffith KA, Kumar B, Chen J, Carey TE, Bradford CR, D'Silva NJ: (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia (2006) 8(3): 163-172.
72. Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, Wong SM, Wang S, Johnson DE, Grandis JR: Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-XL enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol (2008) 73(6):1632-1642.
73. Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A: Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res (2007) 13(7):2226-2235.
74. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 435(7042):677-681.
75. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA: Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 50(6):1181-1189. (Pubitemid 351555542)
76. Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE: ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol (2009) 75(5):1231-1239.